Cargando…
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
In adult patients, acute lymphoblastic leukemia (ALL) is a rare hematological cancer with a cure rate below 50% and frequent relapses. With traditional therapies, patients with relapsed or refractory (R/R) ALL have a survival that may be measured in months; in these patients, inotuzumab ozogamicin (...
Autores principales: | Ravaioli, Federico, Marconi, Giovanni, Martinelli, Giovanni, Dajti, Elton, Sartor, Chiara, Abbenante, Maria Chiara, Alemanni, Luigina Vanessa, Nanni, Jacopo, Rossini, Benedetta, Parisi, Sarah, Colecchia, Luigi, Cristiano, Gianluca, Marasco, Giovanni, Vestito, Amanda, Paolini, Stefania, Bonifazi, Francesca, Curti, Antonio, Festi, Davide, Cavo, Michele, Colecchia, Antonio, Papayannidis, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817094/ https://www.ncbi.nlm.nih.gov/pubmed/34970853 http://dx.doi.org/10.1002/cam4.4390 |
Ejemplares similares
-
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
por: Bertamini, Luca, et al.
Publicado: (2018) -
Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome
por: Dajti, Elton, et al.
Publicado: (2019) -
Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
por: Dajti, Elton, et al.
Publicado: (2021) -
Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis
por: Marasco, Giovanni, et al.
Publicado: (2022) -
Non-invasive tests for the prediction of primary hepatocellular carcinoma
por: Marasco, Giovanni, et al.
Publicado: (2020)